Cite

    Robson, M. E., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Tung, N., Armstrong, A., Dymond, M., Fielding, A., Allen, A., & Conte, P. (2023). olympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European journal of cancer, 184, 39–47. http://access.bl.uk/ark:/81055/vdc_100183610905.0x000023